



# Multisite study of all-oral 9-month DR-TB regimens



*Lesotho*  
 Comorbidity: HIV (>60%)  
 Sample size: 253  
 Bdq, Lfx, Lzd, Dlm, Cfz  
 86% end of treatment success (N=100)




*Kazakhstan*  
 Comorbidity: DM (10%); HCV (5%)  
 Sample size: 704  
 Bdq, Lfx, Lzd and Dlm/Z, Cs/Cfz, or Dlm/Cfz  
 92% end of treatment success (N=450)




*Peru*  
 Comorbidity: DM (15%)  
 Sample size: 50  
 Bdq, Lfx, Lzd, Dlm, Cfz  
 Outcomes pending analysis

# Required investments to protect patients & drugs



# Investment in strategies to rapidly inform policy



*World Health Organization  
recommendations often drive  
local treatment in guidance*